The BPHL Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the SK-HEP-1 human liver adenocarcinoma cell line, with targeted disruption of the BPHL gene. Supplied as a pooled population, these polyclonal knockout cells provide a loss-of-function model to study BPHL-mediated prodrug activation, without the selection biases of clonal isolates. This model is ideal for functional assays requiring complete ablation of BPHL serine hydrolase activity in a liver-derived cellular context.
SK-HEP-1 is a hepatic adenocarcinoma cell line established from a 52-year-old male, exhibiting both epithelial and endothelial-like characteristics. It serves as a versatile model for liver cancer biology and hepatic drug metabolism, retaining certain liver-specific enzymatic activities. The BPHL knockout in this background enables dissection of the enzyme??s contribution to prodrug processing in a liver-derived context, leveraging the parental line??s robust growth and genetic tractability for downstream experimental manipulations.
BPHL encodes a serine hydrolase that catalyzes the hydrolysis of amino acid ester prodrugs, notably converting valacyclovir into the active antiviral agent acyclovir. Acyclovir subsequently inhibits viral DNA polymerase, blocking viral replication. BPHL thus acts as the critical bioactivation step upstream of acyclovir, directly determining valacyclovir??s antiviral efficacy. While upstream regulators of BPHL are unknown, the enzyme may also hydrolyze other xenobiotic esters and endogenous lipids. Knockout of BPHL abolishes this conversion, providing a clean system to study prodrug metabolism and alternative activation pathways.
The BPHL knockout in SK-HEP-1 cells is particularly relevant for hepatic prodrug metabolism research, as the liver is the primary organ for biotransformation. This model allows assessment of BPHL??s role in activating valacyclovir and other ester prodrugs in liver-derived cells, and enables study of compensatory hydrolytic pathways. The endothelial-like properties of SK-HEP-1 may also facilitate exploration of drug distribution in hepatic tumor microvasculature, bridging prodrug conversion and liver cancer biology.
Key applications include prodrug metabolism studies using valacyclovir hydrolysis assays and acyclovir LC-MS quantification; antiviral drug testing by comparing valacyclovir efficacy in wild-type versus knockout cells via viability or viral replication assays; and verification of BPHL disruption by RT-qPCR and western blotting. The model also supports liver cancer cell engineering for mapping prodrug activation networks. For further information or to place an order, contact Ascent Research.
